Replimune disclosed additional layoffs in Massachusetts after the FDA issued a second rejection of its advanced melanoma candidate RP1. The company said WARN notices cover 224 employees across its Woburn headquarters and Framingham manufacturing site, following earlier reductions tied to a prior FDA decision. Replimune’s response links the cuts to the regulatory path forward: management said development of RP1 without timely accelerated approval would not be viable. Analysts cited by the report characterized the company’s next steps as challenging and tied to the need for new funding and a revised regulatory strategy. For the biotech sector, the update reflects how repeated regulatory setbacks can rapidly translate into operating and manufacturing downsizing. It also underscores the financial fragility of mid-stage biotechs that rely on accelerated-approval frameworks to bridge to later funding rounds.